Dermatitis herpetiformis Management

Dermatitis herpetiformis

Dermatitis herpetiformis is a chronic autoimmune blistering skin disease characterized by intensely itchy papules, vesicles, and excoriations, usually occurring symmetrically on the extensor surfaces of the body. It is the cutaneous manifestation of gluten-sensitive enteropathy (celiac disease) and results from the deposition of immunoglobulin A (IgA) within the skin.

Although most patients have evidence of gluten-sensitive intestinal disease, many have few or no gastrointestinal symptoms. The condition follows a chronic relapsing course and responds well to a gluten-free diet together with appropriate medical treatment.

Pathophysiology (Brief)

The main mechanism is IgA autoantibody deposition in the dermal papillae following an immune response to dietary gluten.

This leads to:

• Activation of neutrophils

• Inflammation at the dermoepidermal junction

• Formation of subepidermal vesicles

• Intense pruritus

Dermatitis herpetiformis is strongly associated with:

• Celiac disease

• Gluten sensitivity

• Other autoimmune disorders, particularly autoimmune thyroid disease and type 1 diabetes mellitus

Signs & Symptoms

Typical lesions include:

• Intensely itchy papules

• Small grouped vesicles

• Excoriations from scratching

• Crusted erosions

Common sites:

• Elbows

• Knees

• Buttocks

• Lower back

• Scalp

• Shoulders

Other findings:

• Symmetrical distribution

• Burning sensation before new lesions appear

• Blisters often rupture quickly because of scratching

• Mild gastrointestinal symptoms may occur in some patients

Diagnostic Criteria

Diagnosis is based on:

• Typical intensely pruritic papulovesicular eruption

• Symmetrical distribution on extensor surfaces

• Histopathological findings

• Positive direct immunofluorescence demonstrating granular IgA deposition in the dermal papillae

Investigations

Recommended investigations

• Skin biopsy

• Full blood picture (FBP)

• Liver function tests (LFTs)

• Renal function tests (RFTs)

Special investigations

• Direct immunofluorescence (gold standard)

• Serum IgA anti-tissue transglutaminase antibodies

• Anti-endomysial antibodies

• Small intestinal biopsy when celiac disease requires confirmation

Monitoring

During prolonged therapy monitor:

• Full blood count

• Liver function

• Renal function

• Glucose-6-phosphate dehydrogenase (G6PD) status before starting dapsone where available

Treatment

Treatment aims to relieve itching, heal skin lesions, control autoimmune activity, and prevent recurrence through lifelong dietary modification.

Non-pharmacological Treatment

• Maintain a strict lifelong gluten-free diet.

• Avoid foods containing wheat, barley, and rye.

• Receive dietary counselling from a nutritionist where available.

• Maintain good skin hygiene.

• Avoid scratching to reduce secondary infection.

• Regular follow-up to monitor disease activity and nutritional status.

Pharmacological Treatment

• Betamethasone cream/ointment (topical) — apply every 12 hours until improvement.

OR

• Clobetasol propionate cream/ointment (topical) 0.05% — apply every 12 hours until improvement.

AND

• Prednisolone (PO) 0.5–1 mg/kg once daily for 2 months, then gradually taper to the lowest effective dose.

AND (for extensive involvement)

• Methotrexate (PO) 7.5–20 mg once weekly for not less than 4 months

OR (steroid-sparing alternatives, specialist level):

• S: Methotrexate (PO) 10–15 mg once weekly for at least 4 months with folic acid.

• OR S: mycophenolate mofetil (PO) 1 g/day for at least 4 months.

• OR S: rituximab (IV) 375 mg/m² weekly for 4 weeks.

Specific treatment for dermatitis herpetiformis

• Dapsone (PO) 100 mg once daily for not less than 2 months

Complications

• Secondary bacterial infection

• Chronic excoriations

• Nutritional deficiencies associated with celiac disease

• Iron deficiency anemia

• Osteoporosis secondary to untreated celiac disease

• Increased risk of intestinal lymphoma in untreated patients

Prevention

Recurrence and complications may be reduced by:

• Strict adherence to a lifelong gluten-free diet

• Early diagnosis and treatment

• Regular follow-up

• Monitoring for complications of celiac disease

• Prompt treatment of secondary skin infections

Patient counselling (Important)

• Dermatitis herpetiformis is not contagious.

• It is closely associated with gluten sensitivity (celiac disease).

• A lifelong gluten-free diet is the cornerstone of treatment and helps prevent recurrence.

• Take medications as prescribed and attend regular follow-up appointments.

• Seek medical attention if severe skin infection, persistent diarrhea, weight loss, or worsening symptoms develop.